Sandoz Victoza Settlement Sets Up Face-Off With Teva And Viatris
Novo Nordisk: Sandoz Able To Launch Liraglutide In June 2024
Executive Summary
Novo Nordisk’s cornerstone type 2 diabetes treatment Victoza is set to come under siege from the three largest generics manufacturers beginning in June 2024, after Sandoz became the last of the trio to sign a licensing agreement with the Danish originator that resolves patent-litigation proceedings.
You may also be interested in...
At The Edge Of The Cliff: Five Blockbuster Drugs Set To Lose US Patent Exclusivity In 2023
With the advent of 2023, comes the start of the industry’s next patent cliff, with five products that reached billions in sales at their peak set to lose US patent exclusivity during the year. Scrip takes a look into how the affected big pharma firms are preparing for anticipated market erosion and which generic and biosimilar companies are positioned to benefit the most.
Sandoz Eyes In-House GLP-1 Development – Apart From ‘Key’ APIs
With glucagon-like peptide 1 products to treat diabetes and obesity continuing to gather pace, Sandoz has expressed confidence that it is capable of bring such complex products to market using its vast array of in-house capabilities.
Invega Trinza, Pentasa, and Abilify LAI Top Viatris’ First Complex Ambitions
Viatris spent a good chunk of its recent investor day updating on its complex generics ambitions, especially considering it is set to be missing biosimilars from its armory in the back half of 2022. A proposed move for the first US generic Symbicort was suggested by management.